Back

Impact of a personalized, fire-to-target lipid-lowering strategy in patients with acute coronary syndrome

29 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Improved targeting of risk factors and residual risk Prevention ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Javier Herrera

University Hospital Queen Sofia, Cordoba (Spain)

6 More presentations in this session

Presentation thumbnail
Vericiguat improves MRI-assessed coronary endothelial function in patients with metabolic syndrome or type 2 diabetes mellitus
Doctor T. Harb (Baltimore, US)
Abstract
Presentation thumbnail
Association of dysglycaemic indices with coronary anatomical complexity in non-diabetic patients presenting with acute coronary syndrome
Doctor M. Merry (Ismailia, EG)
Abstract
Presentation thumbnail
Lipid management in patients with coronary artery disease at risk of a first major atherosclerotic cardiovascular event: findings from the VESALIUS-REAL global study
Professor G. De Ferrari (Turin, IT)
Abstract
Presentation thumbnail
Effects of residual risk–targeted therapies on coronary plaque regression: a network meta-analysis of 40 studies
Doctor M. Galli (Rome, IT)
Abstract
Presentation thumbnail
The hypothyroidism paradox: treated thyroid status as a long-term catalyst for LDL-C target attainment post-percutaneous coronary intervention
Miss T. Simonneau (Cordoba, ES)
Abstract

Access the full session

Session thumbnail
Improved targeting of risk factors and residual risk

The Event

Event poster

ESC Congress 2026

29 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
The COR Lipid-Registry: The effectiveness of the strike early and strike strong strategy (SES) in patients with high cardiovascular risk
20 March 2026
thumbnail
Congress Session
5-year outcomes of target all comers randomised trial & prospects of target series clinical trials
29 August 2022
thumbnail
Congress Presentation
ACS Program. Improving secondary prevention in patients admitted due to a myocardial infarction. First year experience
25 April 2024
thumbnail
Congress Presentation
Effect and safety of PCSK9 inhibitor in-hospital use on blood lipid level in the ACS patients: a systematic review and meta-analysis
13 April 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources